PREDICT Consortium - Prospective Early Detection Consortium for Ovarian Cancer

Background, Mission and Goals

Biomarkers to enable earlier detection of ovarian cancer are lacking. Data from randomized trials suggest that the current best available screening combination of biomarker CA-125 plus ultrasound imaging shows no clear reduction in ovarian cancer mortality for screened women, in comparison to unscreened controls.

Though further circulating biomarkers have been identified in studies on cancer cases and cancer-free controls, these biomarkers generally either lacked tumor-specificity (e.g., they may have been related to inflammation associated with advanced cancer), or they had insufficient sensitivity for the detection of smaller and earlier-stage tumors.


To overcome these issues, and with the aim of identifying markers that can detect disease before usual time of diagnosis, we have established "PREDICT" – a consortium of several of the world's largest prospective cohort studies, to facilitate biomarker discovery and validation in samples collected up to 18 months prior to clinical diagnosis.

© dkfz.de

About

List of Cohorts

European Prospective Investigation into Cancer and Nutrition (EPIC) (DKFZ)

Finnish Maternity Cohort (FMC) Serum Bank (University of Oulu, Biobank Borealis)

Janus Serum Bank cohort (Cancer Registry of Norway)

Nurses' Health Study and Nurses' Health Study II (NHS and NHSII) (BWH/Harvard University; H. Lee Moffitt Cancer Center)

The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (U.S. National Cancer Institute), and the Brigham and Women's Hospital (BWH) pre-op biobank (BWH/Harvard Medical School).

Women's Health Initiative (WHI) (Fred Hutchinson Cancer Research Center)

Funding

Organization Name: DOD

Award Name: DOD-ARMY: Army Materiel Command (AMC)/

DoD OCRP W81XWH-19-1-0307

Investigator Team and Collaborators

Key Participants by Site and Study

Coordinating Center: German Cancer Research Center (DKFZ)
Rudolf Kaaks, Ph.D., Principal Investigator and Consortium Director
Renée Turzanski Fortner, Ph.D.

Arizona State University Virginia G. Piper Center for Personalized Diagnostics
Karen Anderson, M.D., Ph.D.

American Cancer Society
Alpa Patel, Ph.D.
Lauren Teras, Ph. D.

Brigham and Women's Hospital
Daniel Cramer, M.D., Sc.D.
Kathryn Terry, Sc.D.
Kevin Elias, M.D.

Finnish Maternity Cohort; University of Oulu
Heljä-Marja Surcel, Ph.D

Fred Hutchinson Cancer Research Center; Women's Health Initiative
Holly Harris, Sc.D.

H. Lee Moffitt Cancer Center; OC3 and Nurses' Health Studies
Shelley Tworoger, Ph.D.

Janus Serum Bank; Cancer Registry of Norway
Hilde Langseth, Ph.D.
Trine Rounge, Ph.D.

National Cancer Institute
Nicolas Wentzensen, M.D., Ph.D.

Patient Advocates
Jean Richardson
Andrea Krull

Data & Biospecimens

Collaboration requests should be directed to Prof. Dr. Rudolf Kaaks and Dr. Renée Fortner

Contact

to top
powered by webEdition CMS